Formerly TOT BIOPHARM, now BioDlink, combining CDMO/CMO and proprietary oncology products. Controlled by WuXi XDC in 2026 but still reporting as an HKEX-listed entity.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY HKFRS / consolidated
747,645,000
-100,369,000 Profit/(loss) attributable to owners of the parent
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
CDMO/CMO revenue was CNY 234,939,000 in 2025; total group revenue includes proprietary products.
Following consolidation into WuXi XDC in 2026, the two groups’ revenue may overlap and must not be added directly. The H1 2026 interim report continues to identify independent listed status.
H1 parent-attributable results moved from profit to loss. The source does not provide a year-over-year percentage, retained as null.
Non-HKFRS adjustments differ between 2025 and H1 2026. They are not directly equivalent to the A-share measure excluding nonrecurring items; adjusted EBITDA is not net income.
2026H1 · Reporting notes
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
CDMO/CMO revenue was CNY 234,939,000 in 2025; total group revenue includes proprietary products.
Following consolidation into WuXi XDC in 2026, the two groups’ revenue may overlap and must not be added directly. The H1 2026 interim report continues to identify independent listed status.
H1 parent-attributable results moved from profit to loss. The source does not provide a year-over-year percentage, retained as null.
Non-HKFRS adjustments differ between 2025 and H1 2026. They are not directly equivalent to the A-share measure excluding nonrecurring items; adjusted EBITDA is not net income.
Unaudited. Hong Kong interim reports and A-share nine-month reports cover different periods.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Formerly TOT BIOPHARM, now BioDlink, combining CDMO/CMO and proprietary oncology products. Controlled by WuXi XDC in 2026 but still reporting as an HKEX-listed entity.
The full 2025 annual report and 2026 interim report have been obtained.
Program / service
Target / indication
Representative stage
Evidence & scope
Outsourced services/custom R&D (group also sells products)
Services / platform
Evidence of services, not clinical data for a drug candidate
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
Complete service-segment revenue, orders, capacity utilization, and project conversion rates have not been separately verified. Group totals are not a substitute for segment figures.
